(Q37599884)

21 August 2017

1 reference

title

Motavizumab for the prevention of respiratory syncytial virus infection in infants (English)

1 reference

21 August 2017

Michelle A Gill

1

1 reference

21 August 2017

Robert C Welliver

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1335-1345

1 reference

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Direct medical costs of bronchiolitis hospitalizations in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Diagnosis and management of bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Ribavirin therapy for acute bronchiolitis: need for appropriate controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Orally active fusion inhibitor of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

A role for immune complexes in enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Noninvasive therapy with helium-oxygen for severe bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903287499

10.1517/14712590903287499

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference